Founded in 2014, Sydnexis Inc. is a privately held, clinical stage biopharmaceutical company based in San Diego. Sydnexis is currently evaluating its patented eyedrop formulation, SYD-101, in a Phase 3 clinical trial to decrease myopia progression in children.